News
A multinational clinical project (OligoG-pivotal-CF) to test the orphan drug OligoG CF-5/20 (OligoG) in a pivotal phase IIb clinical trial for the treatment of cystic fibrosis (CF).
Funding
This project has received funding from the European Union’s Horizon 2020 research and innovation programme part “Health, demographic change and well-being” (call H2020-SC1-2016-2017) under grant agreement No 755234.
First site initiation in Austria
/in News /by philipryeThe OligoGpivotalCF trial is about to start recruiting. On 6th May 2020 the first site was initiated in Wels, Austria and more site initiation visits are planned for the coming months. Pending the normalization of the Covid-19 pandemic, the trial will open for patients at several sites in Europe soon. If you want to know […]
OligoGpivotalCF and Covid-19: AlgiPharma CF Clinical Trial Operations in Europe
/in News /by philipryeWe have now received regulatory approvals from Austria, UK, Germany and Ireland, and ethics approvals from Austria and UK. Ethics approvals from Germany and Ireland are expected to follow soon in order for us to proceed with the OligoGpivotalCF clinical study. However, due to the current situation with COVID-19, we have decided to postpone site […]
AlgiPharma’s Cystic Fibrosis drug candidate OligoG awarded pivotal trial grant of €6 million from EU’s Horizon 2020 programme
/in News /by rogerhenriksenAn EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.